The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISTH 2024 | A detailed overview of the current and emerging gene therapies for hemophilia A & B
Radek Kaczmarek, PhD, Indiana University School of Medicine, Indianapolis, IN, provides a detailed overview of the current and emerging gene therapies for patients with hemophilia A and B. Dr Kaczmarek highlights the heterogeneity in responses to current gene therapies, outlines some of the challenges that remain in reaching a cure, and summarizes some of the alternative gene therapy approaches that are being investigated to overcome these barriers. This interview took place at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Bangkok, Thailand, and virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting and/or speaker fees from BioMarin, Pfizer, Bayer, Spark and Novo Nordisk
Research funding from Bayer
